The June 7 NYSE American compliance plan deadline is the nearest catalyst — failure to submit or gain acceptance could trigger delisting. The pending FDA decision on the PMA supplement for expanded indications is a binary event that could materially expand the addressable patient population.
Price Chart
Executive Summary
Picard Medical issued a shareholder letter highlighting 85% Q1 revenue growth to $1.2M, positive gross margin of 24% (vs -58% a year ago), and debt reduction of $7.4M. However, the company remains unprofitable with a going-concern qualification, faces a June 7 NYSE American compliance plan deadline for stockholders' equity, and has a market cap of only $14M. The letter is promotional and forward-looking, with no concrete catalyst or financial guidance.
Key Financial Metrics
Key Facts
- Q1 2026 revenue grew 85% YoY to $1.2M; gross margin improved to 24% from -58%
- Company repaid $7.4M of senior secured debt in cash and settled $2.1M via equity in Q1
- Raised $5.0M in gross proceeds from a public offering post-Q1; entered warrant exchange eliminating ratchet provisions
- Received NYSE American notices regarding stockholders' equity; compliance plan due June 7, 2026
- Auditors included a going-concern qualification in 2025 financial statements
- First-in-animal trials for Emperor TAH began Nov 2025; second-generation animal testing completed; regulatory approval sought as early as 2028
- Pending FDA decision on premarket approval supplement to expand indications to bridge-to-candidacy patients
Financial Impact
Q1 revenue $1.2M (85% YoY growth); gross margin 24%; $5.0M raised post-Q1; $7.4M debt repaid; cash position not stated for Q1 2026
Risk Factors
- Going-concern qualification and potential inability to achieve profitability
- NYSE American delisting risk if compliance plan not accepted by June 7 deadline
- Regulatory uncertainty for Emperor TAH and PMA supplement approval timelines
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303498 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $6.43 | awaiting T+60 | — | $6.83 (+6.22%) |
Oct 22, 2026 5d ago | S-3 | $7.37 | awaiting T+60 | — | $6.83 (+7.33%) |
Oct 6, 2026 21d ago | 8-K | $8.74 | awaiting T+60 | — | $6.83 (+21.85%) |
Jul 27, 2026 13w ago | 8-K | $0.0878 $0.2096 | ▲ +138.72% | ▲ +134.67% | $6.83 (+7679.04%) |
Jul 15, 2026 14w ago | DEFA14A | $0.1600 $0.1896 | ▲ +18.50% | ▲ +14.79% | $6.83 (+4168.75%) |
Jul 8, 2026 15w ago | DEFA14A | $0.1500 $0.0864 | ▼ −42.40% | ▼ −44.89% | $6.83 (+4453.33%) |
Jul 2, 2026 16w ago | 8-K / 425 | $0.1694 | awaiting T+60 | — | $6.83 (+3931.88%) |
Jun 29, 2026 17w ago | 8-K | $0.1559 $0.0910 | ▼ −41.63% | ▼ −45.25% | $6.83 (+4281.01%) |
Jun 2, 2026 21w ago | Press Release | $13.50 | awaiting T+60 | — | $6.83 (−49.41%) |
Jun 2, 2026 21w ago | 8-K | $13.50 | awaiting T+60 | — | $6.83 (+49.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers